# INVESTIGATION: Long-Term Safety Profile of COVID-19 Vaccines (2020–2025)

**Date:** December 15, 2025
**To:** Public Health Directorate / Academic Review Board
**From:** Senior Epidemiologist & Medical Data Analyst
**Subject:** Comprehensive Review of Proven vs. Reported Long-Term Adverse Events Following COVID-19 Immunization

### Key Findings
*   **Safety Profile Established:** After five years of global administration and surveillance of over 13 billion doses, the safety profile of COVID-19 vaccines (mRNA and viral vector) is rigorously established. The vast majority of adverse events are transient and mild.
*   **Proven Causal Links are Rare:** Serious causal adverse events are extremely rare and specific to certain vaccine platforms. These include Myocarditis/Pericarditis (mRNA vaccines) and Thrombosis with Thrombocytopenia Syndrome (viral vector vaccines).
*   **Statistical Signals vs. Causality:** Several conditions, such as Postural Orthostatic Tachycardia Syndrome (POTS) and Tinnitus, remain under investigation as statistical signals. While associations have been observed, definitive causality is often confounded by the significantly higher risk of these same conditions following SARS-CoV-2 infection.
*   **Debunked Theories:** Claims regarding "turbo cancer," widespread infertility, and population-level mortality spikes attributed to vaccination have been conclusively disproven by large-scale epidemiological data and biological implausibility.

---

## 1. Executive Summary: 2025 Safety Profile Update

As of late 2025, the global medical community possesses an unprecedented volume of pharmacovigilance data regarding COVID-19 vaccines. The "fog of war" that characterized the early pandemic phase (2020–2022) has lifted, allowing for a precise distinction between temporal coincidence and biological causality.

The most significant development in this period was the publication of the **Global Vaccine Data Network (GVDN)** study in 2024, the largest vaccine safety study in history, covering 99 million vaccinated individuals across eight countries [cite: 1, 2]. This massive dataset, combined with 2025 surveillance reports from the CDC and EMA, confirms that the benefits of vaccination in preventing severe disease, hospitalization, and Long COVID sequelae continue to outweigh the risks of rare adverse events by orders of magnitude [cite: 1, 3].

However, the landscape of adverse events has evolved. While early concerns focused on anaphylaxis, 2024–2025 research has crystallized the understanding of rare inflammatory and autoimmune reactions. We now recognize a distinct "risk window" for specific conditions—such as myocarditis within 7 days of mRNA vaccination and Guillain-Barré Syndrome within 42 days of viral vector vaccination [cite: 1, 4]. Crucially, the 2025 data refutes the existence of "delayed-onset" long-term side effects (those appearing years after vaccination without early symptoms); the adverse events identified occur shortly after administration, though their sequelae may persist in rare cases.

---

## 2. Track A: Officially Confirmed Causal Adverse Events

This section details conditions where the causal link to vaccination is **proven** and acknowledged by major regulatory bodies (FDA, EMA, WHO). These events are rare but biologically plausible and statistically significant in large-scale observed-vs-expected (OE) analyses.

### Table 1: Proven Causal Effects (2025 Data)

| Condition | Causal Mechanism | Incidence Rate (per 1,000,000 doses) | Risk Factors |
| :--- | :--- | :--- | :--- |
| **Myocarditis** | **Inflammation**: Hyper-immune response to mRNA/LNP platform; cytokine-mediated cardiomyocyte irritation. | **~10–20** (General Pop)<br>**~140–188** (Males 16–17, Dose 2) [cite: 3, 5] | Male sex, Age 12–30, mRNA platform (Moderna > Pfizer), Second dose. |
| **Pericarditis** | **Inflammation**: Similar mechanism to myocarditis; inflammation of the pericardial sac. | **~5–10** (General Pop)<br>Higher in young males [cite: 1, 5] | Male sex, Age 12–39, mRNA platform. |
| **Guillain-Barré Syndrome (GBS)** | **Autoimmune**: Molecular mimicry where antibodies against the viral vector cross-react with peripheral nerve myelin. | **~2.5–4.0** (Viral Vector)<br>**~0.7** (mRNA - background rate) [cite: 1, 4] | Viral Vector vaccines (AstraZeneca, J&J), Age > 40. |
| **Thrombosis w/ Thrombocytopenia (TTS/VITT)** | **Autoimmune**: Formation of anti-platelet factor 4 (PF4) antibodies leading to thrombotic consumption of platelets. | **~2–15** (Viral Vector)<br>Extremely rare/negligible for mRNA [cite: 1, 6] | Viral Vector vaccines, Female sex (younger cohorts), First dose. |
| **Cerebral Venous Sinus Thrombosis (CVST)** | **Thrombotic**: Often a presentation of TTS/VITT; distinct from general stroke. | **~3.23** (OE Ratio > 3 for ChAdOx1) [cite: 1, 7] | Viral Vector vaccines, Female sex. |
| **Acute Disseminated Encephalomyelitis (ADEM)** | **Autoimmune**: CNS inflammation/demyelination triggered by immune activation. | **~0.78** (General)<br>OE Ratio ~3.78 for mRNA-1273 [cite: 1, 8] | Viral Vector vaccines, mRNA-1273 (Moderna) first dose. |

### Detailed Analysis of Proven Effects

#### 1. Myocarditis and Pericarditis
By 2025, the association between mRNA vaccines and heart inflammation is the most well-characterized adverse event. The GVDN study (2024) confirmed significantly increased Observed-to-Expected (OE) ratios for myocarditis following BNT162b2 (Pfizer) and mRNA-1273 (Moderna) [cite: 1].
*   **Incidence**: The risk remains strongly stratified by age and sex. CDC surveillance data from late 2024 indicates the highest incidence in males aged 16–17 receiving the original monovalent booster (188.0 cases per million doses) [cite: 3]. However, for the general population and updated formulations (2024–2025), rates are significantly lower.
*   **Severity**: Long-term follow-up studies published in 2024/2025 indicate that the vast majority (>90%) of vaccine-associated myocarditis cases are mild and self-limiting, resolving with rest and NSAIDs. This contrasts sharply with viral myocarditis (from COVID-19 infection), which carries a much higher risk of heart failure and mortality [cite: 9, 10].
*   **Mechanism**: The mechanism is believed to be a hyper-inflammatory response to the lipid nanoparticle (LNP) or the spike protein antigen itself in genetically susceptible individuals, leading to transient myocardial edema [cite: 11].

#### 2. Neurological Autoimmune Conditions (GBS & ADEM)
The 2024 GVDN analysis of 99 million individuals provided definitive evidence for rare neurological signals.
*   **Guillain-Barré Syndrome (GBS)**: A statistically significant signal was confirmed for viral vector vaccines (ChAdOx1 and Ad26.COV2.S), with an OE ratio of 2.49 following the first dose [cite: 1]. The mechanism involves molecular mimicry, a known risk with adenovirus vectors. Importantly, mRNA vaccines show GBS rates comparable to the background population, reinforcing the platform-specific nature of this risk [cite: 4].
*   **Acute Disseminated Encephalomyelitis (ADEM)**: A rare but confirmed signal was identified for both viral vector vaccines and the first dose of the Moderna mRNA vaccine (OE ratio 3.78) [cite: 1, 8]. This represents an acute, monophasic inflammation of the brain and spinal cord. Incidence is extremely low (~0.78 cases per million), making it a "very rare" risk [cite: 8].

#### 3. Thrombotic Events (TTS/VITT & CVST)
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) is now a textbook adverse event specific to adenoviral vector vaccines.
*   **Causality**: The presence of anti-PF4 antibodies provides a clear biomarker for diagnosis, distinguishing it from random thrombotic events [cite: 6].
*   **Status in 2025**: With the global shift toward mRNA and protein-based vaccines (Novavax) for boosters, and the restriction of adenoviral vectors in many markets, new cases of VITT have become virtually non-existent in 2025. However, the historical data remains a confirmed causal link [cite: 1, 7].

---

## 3. Analysis of Unconfirmed Signals (Track B)

This section investigates conditions where statistical signals exist ("Reported") but causality remains unproven or debated. These conditions often share a complex relationship with COVID-19 infection itself, creating significant confounding factors.

### Signal 1: Postural Orthostatic Tachycardia Syndrome (POTS)
*   **Status**: **Statistical Signal (Medium Evidence)**
*   **The Data**: Studies published in *Nature Cardiovascular Research* and validated by Cedars-Sinai investigators identified a statistical link between mRNA vaccination and new-onset POTS. The odds of a POTS diagnosis were approximately 1.52 times higher in the 90 days post-vaccination compared to the 90 days prior [cite: 12, 13].
*   **The Confounder**: The same datasets reveal that the risk of developing POTS after a **COVID-19 infection** is significantly higher—approximately 5.35 times higher than after vaccination [cite: 13, 14].
*   **Analysis**: While a "vaccine-POTS" phenotype likely exists (possibly mediated by autoimmune autonomic neuropathy), it is a rare subset of a much larger post-viral phenomenon. In 2025, epidemiologists view POTS primarily as a sequela of the spike protein's interaction with the autonomic nervous system, whether via infection (high risk) or vaccination (low risk) [cite: 12].

### Signal 2: Tinnitus and Hearing/Vestibular Disorders
*   **Status**: **Conflicting Signal (Low/Medium Evidence)**
*   **The Data**: Tinnitus is one of the most frequently reported subjective adverse events. A 2025 study in *Vaccine* analyzing the XBB.1.5 vaccine found **no statistically significant increased risk** of tinnitus in a self-controlled case series (RI 0.78–0.87) [cite: 15]. Conversely, other 2024/2025 studies and surveys suggest an association with new-onset or worsened tinnitus in specific subpopulations, potentially linked to metabolic disorders or anxiety [cite: 16, 17, 18].
*   **Analysis**: The discrepancy likely arises from the subjective nature of tinnitus and the high background prevalence. While individual cases of immune-mediated inner ear inflammation are biologically plausible, large-scale epidemiological data in 2025 does not support a widespread causal link. It remains a "signal of interest" rather than a proven effect.

### Signal 3: Autoimmune Disease Flares (e.g., SLE, Rheumatoid Arthritis)
*   **Status**: **Statistical Signal (Medium Evidence)**
*   **The Data**: A 2025 comprehensive analysis indicates that while **new-onset** autoimmune diseases are not definitively linked to vaccination, **flares** of pre-existing conditions are a confirmed risk. Approximately 10–18% of patients with inflammatory rheumatic diseases experience a flare post-vaccination [cite: 19].
*   **Analysis**: The mechanism is "bystander activation" of the immune system. These flares are typically mild to moderate and self-limiting. The risk of flare from COVID-19 infection is generally considered higher and more severe. There is weak/conflicting evidence regarding vaccination causing *new* autoimmune diseases like Multiple Sclerosis or Ulcerative Colitis; some Mendelian randomization studies suggest a potential causal pathway, but data is not robust [cite: 20, 21].

### Signal 4: Menstrual Cycle & Fertility Fluctuations
*   **Status**: **Statistical Signal (Low Evidence for Long-Term Impact)**
*   **The Data**: Research confirms that COVID-19 vaccination can cause temporary, short-term disruptions to menstrual cycle length (typically <1 day increase) [cite: 22].
*   **Analysis**: These changes are transient and resolve within 1–2 cycles. Crucially, 2025 systematic reviews and fertility trend analyses (BMJ Public Health) show **no evidence of long-term fertility impairment** or negative impacts on ovarian reserve, sperm quality, or pregnancy rates [cite: 22, 23, 24]. The "signal" is real but physiologically temporary (immune activation affecting the hypothalamic-pituitary-gonadal axis), not a long-term injury.

---

## 4. Track C: Debunked Correlations

These conditions have been widely circulated in non-scientific channels but have been rigorously investigated and **disproven** by 2025.

### 1. "Turbo Cancer"
*   **Claim**: That mRNA vaccines cause aggressive, rapidly progressing cancers.
*   **Evidence**: **DISPROVEN**.
*   **Analysis**: Large-scale oncology registries and epidemiological studies in South Korea, the UK, and the US show no association between vaccination and increased cancer incidence [cite: 25, 26]. The "turbo cancer" theory relies on the false premise of SV40 contamination or DNA integration, both of which are biologically implausible and unsupported by genomic analysis of vaccine contents [cite: 27, 28]. Observed rises in late-stage cancers in 2024–2025 are attributed to **missed screenings** during the pandemic lockdowns (2020–2021), not vaccination [cite: 29].

### 2. Widespread Sudden Cardiac Death ("Died Suddenly")
*   **Claim**: That vaccines are responsible for a massive spike in excess mortality and sudden deaths in young people.
*   **Evidence**: **DISPROVEN**.
*   **Analysis**: While myocarditis is a real risk, it is rarely fatal (mortality <1%). Excess mortality studies in 2024–2025 consistently attribute the majority of excess deaths to cardiovascular sequelae of **COVID-19 infection** (which damages the endothelium) and healthcare system strain. Unvaccinated cohorts consistently show higher all-cause mortality and cardiovascular event rates than vaccinated cohorts [cite: 9, 30].

### 3. Long-Term Infertility / Sterility
*   **Claim**: That vaccines cause permanent sterility.
*   **Evidence**: **DISPROVEN**.
*   **Analysis**: 2025 fertility data from 22 high-income countries shows fertility trends returning to pre-pandemic predictions or fluctuating due to economic/social factors, with no correlation to vaccine rollout timing or coverage [cite: 22]. IVF studies show identical success rates between vaccinated and unvaccinated individuals [cite: 24].

---

## 5. Risk-Benefit Context: The 2025 Perspective

To understand the safety profile, one must compare the *proven* risks of vaccination against the *proven* risks of the alternative: remaining unprotected against circulating SARS-CoV-2 variants (e.g., KP.2, JN.1).

| Outcome | Risk after Vaccination (mRNA) | Risk after COVID-19 Infection | Risk Ratio (Infection vs. Vaccine) |
| :--- | :--- | :--- | :--- |
| **Myocarditis** | ~10–20 per million (General)<br>~188 per million (High-risk males) | ~400–2,000 per million (varies by severity) | **Infection risk is ~7–100x higher** [cite: 9, 10] |
| **POTS** | Odds Ratio ~1.52 | Odds Ratio ~5.35 | **Infection risk is ~3.5x higher** [cite: 13, 14] |
| **Heart Failure** | Negligible / No Link | Significant increase (1-year post-infection) | **Infection is the primary driver** [cite: 9] |
| **Long COVID** | Vaccination reduces risk by ~30–50% | ~10–30% of infections result in Long COVID | **Vaccine is protective** [cite: 31, 32] |

**Conclusion**: In late 2025, the data is unequivocal. The "proven" long-term side effects of COVID-19 vaccines are specific, rare, and generally mild compared to the disease they prevent. The most serious signals (TTS, GBS) are linked to viral vector vaccines which have largely been phased out or restricted. For the currently dominant mRNA vaccines, the primary verified risk is myocarditis, which is rare and typically less severe than viral myocarditis. The vast majority of "reported" long-term issues (e.g., turbo cancer, infertility) have no basis in high-confidence medical data.

---

## 6. Reference List (2024–2025 Sources)

1.  **CDC/ACIP**. (2024). *COVID-19 Vaccine Safety Technical Report 2024-2025*. Centers for Disease Control and Prevention. [cite: 3]
2.  **Faksová, K., et al.** (2024). "COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals." *Vaccine*, 42(9), 2200-2211. [cite: 1, 2, 33]
3.  **Xu, S., et al.** (2025). "Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study." *Vaccine*, 62, 127548. [cite: 15]
4.  **Jasilioniene, A., et al.** (2025). "Association between the COVID-19 vaccination campaign and fertility trends: a population-level time series analysis for 22 countries." *BMJ Public Health*, 3(1), e001410. [cite: 22]
5.  **Kwan, A. C., et al.** (2024/2022). "Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection." *Nature Cardiovascular Research* (Cited in 2024/2025 contexts). [cite: 12, 13, 14]
6.  **Global Vaccine Data Network (GVDN)**. (2024). "99 million people included in largest global vaccine safety study." University of Auckland. [cite: 34, 35]
7.  **European Medicines Agency (EMA)**. (2024). "EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025." [cite: 36]
8.  **Public Health Communications Collaborative**. (2025). "New study revives myth that COVID-19 vaccines cause 'turbo cancer'." [cite: 25]
9.  **GlobalRPH**. (2025). "Autoimmunity and COVID Vaccines: Risk of Flares or Protective Benefits? A Comprehensive Analysis." [cite: 19]
10. **Frontiers in Pharmacology**. (2024). "Cases of tinnitus have been reported following administration of COVID-19 vaccines." [cite: 18, 37]
11. **The Lancet**. (2025). "For kids, COVID infection riskier than vaccine." (Referencing UCL study). [cite: 9]
12. **BMJ Global Health**. (2024). "Vaccination in pregnancy and reactogenicity outcomes." [cite: 38]
13. **Pfizer Medical**. (2025). "Analyses of Myocarditis and COVID-19 Vaccines." [cite: 10]
14. **Yale Medicine**. (2025). "COVID-19 Vaccine Comparison: 2024-2025 Updates." [cite: 32, 39]
15. **Contagion Live**. (2025). "mRNA COVID-19 Vaccines and 'Turbo Cancer': The Latest Myth That Won't Disappear." [cite: 27]

**Sources:**
1. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHqL1hHhXqG1AgKR87KeKDf-Ji4D_rlbpD3S-qyM0AHH7MvpmYBs-TLEtoQD7S3Z2YOVJ2WPiiZqsI6kcM6bLTPJc9OOvPK7zPyq2aiLknJpLV9Ux0AcbOAtq5-kr_f)
2. [ku.dk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuWRYs3j6eLQZqLmI6lZkJ0heewaIh0GLrI1ATnRL1MMHDZ41BLscQ4wp4LYapg-f9mEBQxTgGkUzRr4d2i8s3lD4y3Dp0pZuqNAbu9DlSAkZ17DUEXxhQxsZbJZHGjJcV-ZFeEitYfzqfwdvuhkuFRegDyaa0Ka4JM4ItNHxL1WiGJVgeOB348T7c2AuD7abQgG-9zpeFnVJu3xkyCMQLPZy0dHn0)
3. [cdc.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEzHmTkoJ55shOaoWzODAvP3EyxAAO6MTHpkluieyWYCFAXY2RY_04mky2XT3O_CyasOlYM2YI5MwDPeDhZ4Bvw6WtotflTvpsMGcpF7usPkBazDKMCJYHu8K_LGyePkBJW0naTMBBvQl47YGuzvhOIbJxSGm49q94U88t3Rzc=)
4. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHwBXjNhVJgVbhhgsyi0SYc8S4hCXaPtLRZPkPv8hqOq9Zfv2QQ16niQ-lXtan4M5cvvX5qm5LG9sgBAubKfunY_ga1gEOtCtzr6sxuTPhQ8dqOYmV-l0qJHT9G5_fHsan0pqMWik4O)
5. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEqemeBspQ-9ipkVXH6wBRNINq114Pyf3OT6UoM55qPQoFmmL6GcpBikRZqcFgOnZWaSbMUXZS4c1WfW7nGLoUGOHk7Cl3K-JWzLgw6ob2yxoGeh_Dn51LMbGFt9z9h)
6. [semanticscholar.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHG0hPHTWQMdsIj7hyK6YqmdSJfb-HFZGWlTc79GEUr5gHkjtnKu84OR3a4Ltvit5g6PeANL3Rfky3aUqhOk4lNyfILfN3ib2JVBLusq0oVDhtAf9XMD69y38eTHW8JpNbTOyUm2vfmZtfbmAXjQufk3Yle6-FTHM8h-lGmxb3Cbe4FWQ==)
7. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEziGkUZ2zCcIv2lSCNXx9B2lYsMTkVv_IVvnrUa02hnaeH4ib0D0bo6w3MZnweke3wLxA1DGxvP4cmzTThIg8fY4aI2F-1UnLM6Y-vtH7c1l9iKzYM3_572x8IRvlgWCIv9DpdgUVK)
8. [tandfonline.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1h-Bs7USh_S_GG4O0Q1khgnxuMKkeoE5mTrgUcrzYMJJBFiLB2okS_4ItfiMGGNV9saPNiLkonl9_B9X1I4EbMj-9SnEO3pT7dTHUoKW2H5GBkdd0Qns2d6itRrhkn19vgSKKXpSQboxi8l9K8Ch2PYRgsA98HQ==)
9. [webmd.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEK_f0r_9OUjzdfvSNnVwKzAf1WyPTWQqF72oq5Gp0QMdlxvbnc1KrXiihc9UpmNzVhTZVom67DDbY6K135HgJVyXhY3c_hBVbIFBULI6IbfjgqYABGXpVudhoEbwtn01bKLAOTaMR9DkKYSIsutU3T6QB1-a3gkvPoUEHFfL4eR2bRQ5D9ejptUchKgif8Q7IOXZu_Hv5TxLLC60hJnztz)
10. [pfizer.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5_K4KWJF3anfrFuz1DPf59c8vc00ax_aSFm1S17u4tEaRnz-eHwepr-MjjNQGzuXWzorASPldWrInY7u0spZCawsxDEp1dEuO7rVKKqKTtCjkIOmyERhkq_sWmLqDSEOdhYhtL17JKN8ZD3OB--e-hHvOqRPoPmknopxRcnKV44quvSvLDQgbXVSqyfywLySO23yrFfw2AcOcJ48a7GyEQw==)
11. [naturalnews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGdCYOUjux5mWV8t8NKmmqkn9uIjyQKgmQvIQ3FDJTA3X6AEptnIsp6OU17t9QyAJwtkHTHltJn6N0ts7_hkha_CP5VI_0CYCVTAdIhnmFV4d3AdfmL0CMU64ro8OnrxaKHOrsL5VNu2F5v2ZjYNk1IIVYeefoJ2e_tPjTNZrfEO6Tri9oAfUX7oicE9QzV)
12. [cedars-sinai.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE7YhdltCnTu2IEVOmb9KjHkewEJyTZu-M7CC2Fq2xcxOADHGQhTryZZdnVMeTfG0JCc90-sT-7WzFPc3178YXvw00dG1W3k9VW_ha2yacwMJRdxdmexrm7YXFqegfVhzfL58UhG1mNjWKikyutC33ljKRoN8Nh_AEPj4Z6HfNULaAirgQ5CcSH8kUsxA-vNjh-2kCphqF_4Ya9cA==)
13. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAz-RltxDyieTeahS9iaDTJOoq91mdzi71wWFcxeV8D2Bpw4ZOPlL216I_KOOVvA3YYR92iP3vRlLNCCVA2Y5t0IMv3E8gItA6ceohdAVMpQH8zZC98Wa7AMkGhA7S)
14. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6m64ZnEubYrCL5ZJAdYbajtww5PklJ10uXJ7Eu9TBUdOGou5m5Wv26geE7Uu1xA-1cwY_8x67nsemqtsyYFvknnibMcRxGbanl5QuAItF2BxB1wvj0koTbEwYzyMMnsMaeGwsRDI=)
15. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFwkvYRPK-kLjuwwJua9jOM0MROmrZ5onstPwQatgQxrVwzJBd3CRxnIL56a8AjkH4isRDx0fpVs3PoyoyxFaKEW958jZIHOxhKbUsTsFVzy7XT1SovW234WPUIFI8k)
16. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkW0azwtATTx7yirglPe9br203qgPGuaZe0EbnLu0jcyQ2n6HlehM7uiCBI4-Qwnx8EiKxupSV_lQug_W1MfaM7u2ytsTZ8a3xxgY6GqRbMkaTRSKuF4rBUgS5v1o9gH9bg43jQtQ_7hZ1FhzlTgKupVo4-Ei56-wXE2gFJNZsYrG28oNVccMpA8cuosb7ivY=)
17. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENuedAmmPqPibzpp0oL0-kHh5rXR8J4TLvNdsMJBeWdpgFkBbGc_KnauiiEprq9sgbHdcAVEvfRiuFifzXQLd0e5mpNi2XMxncjkVcrUTpbRCve842utUFQb0_EG9kJl2O3I6d1S2M-XiRA1CcrdBI8BnnXSixGGlC_4exZ346kkJLBoifL9HCR5taTlxScU7G-2HvWNCnFA==)
18. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErxzgVXVWAvPeBEWR_77a-BWgOFvXhTVzyhjy-76WsN_ADDZecTARslGuee5ecJ-UAD28kchAmJTQ3wBs-9rK6cifZMQh0Qw-zDwP39ya5L05eyPToj2MCXGFGvJuH)
19. [globalrph.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFytLWiDq5LAfAs48w9Ing1ENbh6151hofDrzkxNQMh1JDSu0_Y1VkysU0agK4lKxuQSidHJQIes0tHJPN_JfauHai8VC2k7Hb4Glx1Io9gUv-77Dqi5TGVi_pt7yVHs6k6iXyohERBa0pIQ6g7RihHD9P9Ck4IMzZJeGQmzlu338PhoA1IMWSpXh3hYMXhvEhzxfaX7l2N04Mz_Jn8WbjWnxs9d3GvuS5BLFoWtpqBFoviMHU3y7bM4kvw9hX2wC49lobC0Jy7VgtLTPHHm8g-BCJbkQ=)
20. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEQzthCjRL_Wc201AMz4T7nIIvrD2N8IK2J43dSPfjNOMB7lV3DXMcTq3oa58egQDGXV4VNm6VR3aj23w9XwpMivDS7jJVtLaZhHlwfjWx_EjPmT7W-84k1hDV0w0EFeKRlR5rQizXNe25XZSZpop5YJfL5ymQAbORXMskI2E3N1gCfwXKyjPw3nCREQvmm8k4=)
21. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-n-8VEieGdh54feSynxxFqS92TENF1KZFiuX7SEGr66wm883LTwJUGo3D56R_njYW9JJktjb0aEUj20wPvnLH0tEo8xiZCWivuTYZ8jZ79CZHlt_StITa_sPMko-jbHwsy7r08VYI)
22. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG4GxV2aEekFYFfOsi3TSs5MmE1U42GXyED8pAgZ2c4WqkyFsx1og6XwYOkb-5MLTCuEUJV0jEUZqP9R-xWgftTsr2T0sHKbfJdtLpNMvMcCcb929SkLBGEp6vZ7IKF)
23. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5urAiX5AYFHyiQMoS7VsG6J5RVH6IFCzrdEkTUnx3R4IKbgwcPTsW32sxyrw-B6ez3Xc_ijf7CAFyCbiRc382sBx331GyxUXX1u7pveZxm6ruotJkpZiuREih_8T4buOB7WEqmlw=)
24. [sdvoice.info](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGMrcQkEb7bu7Q73CtEowQH-Rb_gbRQCcKhbmggTpnrJgdUOz2qR3DnMnQrd7K4svM9YbxcqW35fy1etoUjvVLSzIs8S-2x9nIw2AStmJIisdI0CBiyywXphL9AmuRm0BkVnsOGJwY0dYtgMxs1aOSzvZqmrKoEG8oZ-2LtjONUg-ozhMFeMABVmK6xjO-vX3Hu19pdtAQ=)
25. [publichealthcollaborative.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQERcsdpif3TpWs_YzY5g4JxyirKOK2PAHeqb80BuCTiVaJLa2bI727vU_Xz9dlxZkkZEGJ2ysRoMLFcA7k5rFM96yc41beolwXE9x9IYXAVTPZEy5x6eVgPCKPcMv_YblzKa-DekcyXCHvPRiMVRDPmJFN0zwWDDi20UWaDQ7SAZ2L4A-x8N_AaAVgdGNDo29rUqZlTQ6jWnAeuu7JED8pqU1hH)
26. [feedback.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEAV8kfEeqVy_Gno1Q4cUNiTiwJsN6rD0d6-UQaOV5IL771IqIOhqOD9kZjiWj_n5Tvqp8ay4YwW0LHZi_MQb3cGdxD7Uxi1WeTaCqwwH1gebixUrS-B-GbIhjVb2bdSceKqgZlGkAN69wp0f1pSsDP9rP6imn81kE0CuX8Hj7IAlVTrNjDprnMlk5pGP2WFqV0jXgd)
27. [contagionlive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrAYKObtYNn9mOlEurwMa_wgh8ydPkIpqVmIZopSsY0EyLhl7d65fqAtYmC93mj0SvOeKyGACKmTZVUOLdga5TDCETngWVCYn1EEnP0IL5ebdrb4NXp3S12EShsqWBI4mKYv69E86196nDJjh2xlNOkm6JimkR0_18PVda80lWGH5r-s35lHbt7Y2TtufW7SJYeyDyPa7vrWCXlpKoyCObflK_8w==)
28. [ezra.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfOucaig57KUeH6NwZjGq4OCLNgr9m7PTvbJYY6r3SmLAyKB48uiVjU8E8zSLOn0ONz7OyGb4f5K52pyowSM9CwjIWhYmxkbc8EJWLMLuPF1eoddX-GmMoi8FuRpM=)
29. [ezra.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFX1Xnxu8bFznu2Ye5hYSukbhfrzE9Vd_2AgzrlzAOBKVTNCmP6F9kjCRwBcQUk2EOR6LgplGF3vRR9XE228o14Rgu01lG3L3CEybFYM407dBrKN0ey0gY=)
30. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4ezpygSDo4lyeUOl4bNwXlX6B4vtNhdrgsQB7ZM8FrulzDFfROBUY5T4lvg8u-6VqleK8HJFLfVuWwQgZuMOG_Lant-d7NdiNqsorBTO2r7eF4JsoarkVP3RVye_1-Tm1EebCpo7z)
31. [cdc.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxsMyfvUnjP1GgVHsVyiGrZ-cCXz2zF0t_oHqFqxzQcAA7BjlH29ScnW1T_Pyp0QnomepCROAoHyBIuax0GupdGaYInpUj5pxNaNzN-RnD-5PhE0ZqoV0xxfwi9oOksTvKtGNYOrjCCCuhNOKY_3FPLkUtdy0X3Vc=)
32. [yalemedicine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF_B0m7w-4T2yyjJeYxk0GXiFDKwFU8Fl9hNUk1iFt-t8ElNuQ5jNb32WTRTqj-h6Rf73wQ7gVwJ2IcR3sPhcMIeLlkur4X0Tez5rKL0f4R3orsVfJsx7Co47xK1DhSUIW5lowp-MgJQZ3kh60Qm1UEweI=)
33. [colab.ws](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNvW_lEbI2CANKexlBXmFYvEsFtNroH6QDmy2INkAk5MEi7vVDJOlnZc7cINZZ3XpXpKHKcdujBnNWsjShatjguopqGTlqZ_gsvIm78jn8hAUGoE1dBzU4GlF__LGOrwBcQnxl7_Ya2ApmNZPmHQ==)
34. [brightoncollaboration.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGHJvb3_lHJmA0nJApP1y6QQvIO_pJVkGAfCf2u2zmDq8-Lzoqt2bljmglJVIuyFXTyNtGevW4qqu89t2l47TkcELCr-MomF_GimLmasm4TKbpORRyBp1AvBQ6xCuFiyigJgoX0oRbI1sNxW7D9o8ICJr8U1ExRtiYFTpQEg0aGHREfbS767-9tlgid5Swn)
35. [auckland.ac.nz](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLGl7AqM6y9qJNdRAVTxisqhn95snzQVojtPDVA0J9o4PMmiKuc_tbpxaIeqwLp2q4UhS07pb494NmUpRe3jQ_MZv7tJUe85XHga79hbSkQsERMmPpAlmxd1TolPlTb68J008XSjqyr89z7LoLvBzj429B1px90DgzuDwPD7qlN2DEvhmhQiNaSEZaLKlSy3yEA4ocj9rl8A==)
36. [europa.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3s_ING8_Ak3AX1ddHCrfytLuhA_ekkAtOBtR7WiQNlkyMV1NvTiQ04y6nW2C5ta-9XOiu4p1ON2kP24l4lUx_OW-kVmklHgW_27kq9zXxlmB7TSAIl-4ogPUiKGMTZcyFR_ckxnZ5CvUMMHVxlLj5SSeHkiiduaBg5DWCI1dja_BUyf7BypNC99WvrBcTsyq_BoqGNdGlmDhEe1dhH7T4OSCJTeaKgFfkUpT-cjpP6E8knKakmMMSCuG6NAxpvFl8ZfC2fuWnOfC7eYhO)
37. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH_gIpRdA7RqBrsC9wWKzdGigGO9eiukECwVIzqkL-98bXRklLO3e747ZuPXeiKqGkupCkhvQ6DIWt5qynWN6gHYbmfSmimzTC0m30XFe6VgasBobwK3NdmxvnNjq1pwsduurb9afG4)
38. [bmj.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEzQej-vf8ZioM4UEpxlvBJ2vFlsgXgbD1ua0lz-te3zy7LMidpacV1iSG8hFQYD0EeV6pbpyNVnxYmaKnbkCvF7YehjP0-Yc2GpTjTW6OjztTQTQIKQKmpsL0B)
39. [yalemedicine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQERjnx3g8SyWziejr8zqZOCjl2joVuF830Ho_ZDR8yukxUiO676xOlBKAdQEgLPY3kmZFyrY-fhiXdCWJ4CRMl2BfaN-_2os3v54tk-N2rma0rZhZkzaZKN5HpFttXsr_vloWCS4eVOwRE9-_c4N-_tpYIjAfKIKw==)
